z-logo
open-access-imgOpen Access
In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors
Author(s) -
Jennifer A. Lee,
Nikolett M. Biel,
Raymond Kozikowski,
Dietmar W. Siemann,
Brian S. Sorg
Publication year - 2014
Publication title -
biomedical optics express
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.362
H-Index - 86
ISSN - 2156-7085
DOI - 10.1364/boe.5.001965
Subject(s) - sunitinib , in vivo , medicine , blood flow , renal cell carcinoma , flow cytometry , blood vessel , angiogenesis , pathology , biomedical engineering , cancer research , biology , immunology , microbiology and biotechnology
Vascular targeting agents on their own have been shown to be insufficient for complete treatment of solid tumors, emphasizing the importance of studying the vascular effects of these drugs for their use with conventional therapies in the clinic. First-pass fluorescence imaging combined with hyperspectral imaging of hemoglobin saturation of microvessels in the murine dorsal window chamber model provides an easily implementable, low cost method to analyze tumor vascular response to these agents in real-time. In this study, the authors utilized these methods to spectroscopically demonstrate distinct vessel structure, blood flow and oxygenation changes in human Caki-2 renal cell carcinoma following treatment with OXi4503 alone, Sunitinib alone and both drugs together. We showed that treatment with OXi4503 plus Sunitinib destroyed existing tumor microvessels, inhibited blood vessel recovery and impaired Caki-2 tumor growth significantly more than either treatment alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here